14 Oct 2014

Cypher Genomics Presents Two Abstracts on Identifying Disease-Causing Genetic Variants at ASHG 2014

Cypher also launches Mantis 5-for-5, a trial access program for genome interpretation

SAN DIEGO – October 14, 2014 – Cypher Genomics, Inc., the genome informatics company, announced today the platform presentation of two abstracts at the 2014 ASHG meeting being held October 18 to 22 in San Diego. These studies highlight how Cypher’s technology, which incorporates commercial access to the Scripps Wellderly Cohort as a genome reference population, can report known disease-causative genetic variants as well as identify novel causes of disease.

Cypher is also launching a limited-time, trial access program, called Mantis 5-for-5, for researchers and laboratory directors to use MantisTM, Cypher’s genome interpretation technology. To learn more and sign up for Mantis 5-for-5, visit Cypher at booth #1525 or click here.

Cypher’s core products include Mantis, a genome interpretation software offering with clinical-grade accuracy, and CoralTM, a service offering for biomarker discovery and novel target identification. From human genome sequencing data, Cypher provides rapid, automated whole genome data interpretation at scale for clinical laboratories, pharmaceutical studies and population genomics.

Cypher will be giving two platform presentations that highlight the impact of the technology on finding clinically meaningful information in human sequencing data to improve medicine and patients’ lives.

Abstract 112: De Novo KCNB1 Mutations In Epileptic Encephalopathy will be presented by Ali Torkamani, Ph.D. on Monday, October 20 from 11 am to 11:15 am in room 6DE, upper level of the San Diego Convention Center.

Abstract 317: Frequency of “ACMG-56” Variants in Whole Genomes of Healthy Elderly will be presented by Lauren Ariniello on Tuesday, October 21 from 10:30 am to 12:30 pm in Room 29, upper level of the San Diego Convention Center.

About Cypher Genomics

Cypher Genomics is a leading genome informatics company offering a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing. The proprietary, automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics’ market leading sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use and pharmaceutical companies to discover biomarkers from whole genome sequence data in sample sizes typical of early stage drug development studies. Through MantisTM, the genome interpretation software as a service offering, and CoralTM, a biomarker discovery service, Cypher Genomics can improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions. Cypher Genomics is located in San Diego, California.

For more information about Cypher Genomics, visit www.cyphergenomics.com and follow us on Twitter @cyphergenomics.